Evox Therapeutics Limited products

Targeted delivery of nanoparticles is an area that has been intensively researched. Targeted drug delivery has a role to play in the delivery of many if not all drugs, but targeted delivery systems are critical for the delivery of nucleic acid-based agents such as siRNA and CRISPR-Cas technology.

Evox’s proprietary protein engineering technology enables loading of protein therapeutics and tissue targeting moieties onto the surfaces of exosomes, which allows targeting and display of therapeutic proteins to an organ of interest.

Nucleic acid-based therapeutics constitute a core therapeutic modality for Evox’s development programs, and we have sophisticated capabilities for the loading of various nucleic acids (primarily RNAs) into exosomes.

The Evox portfolio includes granted and pending applications in the world`s major pharmaceutical markets, including USA, Europe, Japan, China as well as various other jurisdictions. In addition to the patent portfolio Evox also safeguards its intellectual property by the maintenance of several trademarks, copyrights, and trade secrets which together form broad and deep protection for the company`s intellectual assets.

The second urea cycle disorder indication to be targeted by Evox is Citrullinemia type I, which is caused by a mutation in the ASS1 gene leading to a deficiency in hepatic enzyme arginosuccinate synthetase (ASS) that results in high levels of citrulline and ammonia in the blood.